Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a bedside ultrasound predict a deadly sickle cell complication?

NCT ID NCT07782489

Diagnosis Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This study tests whether a bedside lung ultrasound, done within six hours of arriving at the emergency department, can help diagnose acute chest syndrome in adults with sickle cell disease experiencing a vaso-occlusive crisis. Acute chest syndrome is a serious lung complication that occurs in 15-20% of these crises and is a leading cause of death. The ultrasound, performed by an emergency physician, checks 12 lung zones for fluid, consolidation, or other abnormalities. Researchers will compare the ultrasound findings with the final diagnosis to see how accurate the scan is.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pleuropulmonary ultrasound
What this could lead to
If accurate, this bedside scan could help doctors identify sickle cell patients at risk of acute chest syndrome earlier, potentially improving care and outcomes.
What could go wrong
This is an early, single-center study, and ultrasound findings are kept hidden from treating doctors, so real-world benefit is unproven. Operator skill may also affect results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with sickle cell disease presenting to the Emergency Department of Henri-Mondor University Hospital for a vaso-occlusive crisis. Eligible patients will be aged 18 years or older and have sickle cell disease of genotype SS, SC, or S-beta-thalassemia. Patients must be affiliated with a social security system and must have received study information and provided written informed consent before participation.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Age ≥ 18 years * Sickle cell disease: SS, SC, or S-beta-thalassemia * Presentation to the Emergency Department for vaso-occlusive crisis * Patient affiliated with a social security system, either as beneficiary or entitled person * Patient informed about the study and having agreed to sign a free and informed consent form to participate in the study Exclusion Criteria: * • Diagnosis of acute chest syndrome already established upon arrival at the Emergency Department * Pleuropulmonary ultrasound showing no abnormality but not having explored all twelve areas of interest \[Appendix 1\] * Patient already included in the study during a previous Emergency Department visit * Patient under guardianship or curatorship * Refusal to participate in the research

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute chest syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute chest syndrome Emergencies sickle cell disease Vaso-Occlusive Crises

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute chest syndrome Sickle cell disease (SCD) Vaso-occlusive crises

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.